What is Yubo International Biotech Limited's earnings per share (EPS)?

Yubo International Biotech Limited (YBGJ) reported diluted earnings per share of $-0.01 for fiscal year 2025. This represents a 50.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Yubo International Biotech Limited Financials

YBGJ

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows Yubo International Biotech Limited (YBGJ) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI YBGJ FY2025 2026-05-15

Yubo’s operating model currently looks like externally funded maintenance, with negligible sales unable to carry the cost base.

In FY2025, financing inflow of $850K almost matched operating cash burn of $843K. Cash still finished at only $8K, and with a current ratio of 0.2x plus liabilities that were entirely current, the company’s funding posture looks roll-forward rather than reserve-building.

FY2025 revenue was just $12K while operating cash outflow was $843K, so the business is not yet being sustained by customer demand. FY2024 showed the same pattern, with sales of $3K against cash burn of $1.3M, making this a structural commercialization gap rather than a single weak year because the cost base remained substantial even when sales nearly disappeared.

Liabilities fell from $4.8M in FY2024 to $2.8M in FY2025, which eased some balance-sheet pressure. But assets were only $847K and equity remained negative at -$2.0M, so the company still has a thin financial cushion and limited flexibility if outside funding tightens.

Financial Health Signals

Financial Profile 13/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Yubo International Biotech Limited's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Yubo International Biotech Limited has an operating margin of -9614.6%, meaning the company retains $-9615 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -51006.3% the prior year.

Growth

Yubo International Biotech Limited's revenue surged 256.0% year-over-year to $12K, reflecting rapid business expansion. This strong growth earns a score of 0/100.

Leverage

Yubo International Biotech Limited carries a low D/E ratio of -1.43, meaning only $-1.43 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 80/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Yubo International Biotech Limited's current ratio of 0.24 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Piotroski F-Score Weak

3/9

Yubo International Biotech Limited passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Low Quality

0.78x

For every $1 of reported earnings, Yubo International Biotech Limited generates $0.78 in operating cash flow (-$843K OCF vs -$1.1M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$12K

YoY+256.0%

5Y CAGR-60.9%

Yubo International Biotech Limited generated $12K in revenue in fiscal year 2025. This represents an increase of 256.0% from the prior year.

EBITDA

-$1.0M

YoY+36.2%

Yubo International Biotech Limited's EBITDA was -$1.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 36.2% from the prior year.

Net Income

-$1.1M

YoY+39.2%

Yubo International Biotech Limited reported -$1.1M in net income in fiscal year 2025. This represents an increase of 39.2% from the prior year.

EPS (Diluted)

$-0.01

YoY+50.0%

Yubo International Biotech Limited earned $-0.01 per diluted share (EPS) in fiscal year 2025. This represents an increase of 50.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$8K

YoY+14.9%

5Y CAGR-64.3%

10Y CAGR-3.9%

Yubo International Biotech Limited held $8K in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

N/A

Margins & Returns

Gross Margin

66.1%

YoY-10.2pp

5Y CAGR-25.5pp

Yubo International Biotech Limited's gross margin was 66.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 10.2 percentage points from the prior year.

Operating Margin

-9614.6%

YoY+41391.7pp

5Y CAGR-9562.1pp

Yubo International Biotech Limited's operating margin was -9614.6% in fiscal year 2025, reflecting core business profitability. This is up 41391.7 percentage points from the prior year.

Net Margin

-8736.7%

YoY+42434.7pp

5Y CAGR-8684.1pp

Yubo International Biotech Limited's net profit margin was -8736.7% in fiscal year 2025, showing the share of revenue converted to profit. This is up 42434.7 percentage points from the prior year.

Return on Equity

N/A

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

N/A

YBGJ Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$12K+256.0%	$3K-99.4%	$605K+479.8%	$104K-91.6%	$1.2M-8.1%	$1.4M
Cost of Revenue	$4K+409.5%	$822-99.6%	$185K+259.3%	$52K-87.8%	$424K+270.8%	$114K
Gross Profit	$8K+208.3%	$3K-99.4%	$419K+696.1%	$53K-93.6%	$821K-33.8%	$1.2M
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	N/A
Operating Income	-$1.2M+32.9%	-$1.8M-48.1%	-$1.2M+0.9%	-$1.2M+21.9%	-$1.5M-116.8%	-$712K
Interest Expense	N/A	$50+113.3%	-$377-264.6%	$229-46.4%	$427+14333.3%	-$3
Income Tax	$0	$0	$0	$0	$0	$0
Net Income	-$1.1M+39.2%	-$1.8M-48.6%	-$1.2M+0.8%	-$1.2M+21.9%	-$1.5M-116.7%	-$712K
EPS (Diluted)	$-0.01+50.0%	$-0.02+80.0%	$-0.10	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$0	N/A	$0	$0	$0	N/A	$0	$0
Cost of Revenue	$0	N/A	$0	$0	$0	N/A	$0	$0
Gross Profit	$0	N/A	$0	$0	$0	N/A	$0	$0
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Income	-$289K	N/A	-$310K-24.2%	-$250K+46.6%	-$467K	N/A	-$533K-13.2%	-$470K
Interest Expense	N/A	N/A	$18-21.7%	$23+221.1%	-$19	N/A	$49+188.2%	$17
Income Tax	$0	N/A	$0	$0	$0	N/A	$0	$0
Net Income	-$273K	N/A	-$310K-34.7%	-$230K+47.1%	-$436K	N/A	-$621K-17.7%	-$528K
EPS (Diluted)	$0.00	N/A	$0.00	$0.00	$0.00	N/A	$-0.01	$0.00

YBGJ Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$847K-44.8%	$1.5M-7.9%	$1.7M-29.0%	$2.3M-48.8%	$4.6M+87.6%	$2.4M
Current Assets	$668K-2.2%	$683K-5.9%	$725K-3.3%	$750K-29.1%	$1.1M-44.6%	$1.9M
Cash & Equivalents	$8K+14.9%	$7K+10.3%	$6K-65.1%	$18K-33.8%	$28K-98.0%	$1.4M
Inventory	$24K-35.0%	$37K-82.8%	$215K-33.4%	$322K+96.1%	$164K+144.7%	$67K
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.8M-42.2%	$4.8M+37.6%	$3.5M+20.5%	$2.9M-38.2%	$4.7M+269.4%	$1.3M
Current Liabilities	$2.8M-40.9%	$4.7M+39.1%	$3.4M+34.6%	$2.5M-9.6%	$2.8M+118.4%	$1.3M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$2.0M+42.9%	-$3.4M-85.7%	-$1.8M-226.1%	-$565K-330.9%	-$131K-111.2%	$1.2M
Retained Earnings	-$7.7M-16.2%	-$6.7M-36.3%	-$4.9M-32.4%	-$3.7M-48.5%	-$2.5M-163.6%	-$943K

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$710K-16.2%	$847K-11.1%	$953K-9.4%	$1.1M-9.8%	$1.2M-24.0%	$1.5M-7.2%	$1.7M-4.3%	$1.7M
Current Assets	$598K-10.4%	$668K+2.8%	$650K-1.4%	$659K-3.8%	$685K+0.4%	$683K-5.7%	$724K-4.9%	$761K
Cash & Equivalents	$10K+28.8%	$8K-26.2%	$11K+4.9%	$10K+6.6%	$10K+39.3%	$7K-12.7%	$8K+4.3%	$8K
Inventory	$24K+1.6%	$24K-36.6%	$38K+0.6%	$38K+1.2%	$37K+0.7%	$37K+462.1%	$7K-92.4%	$87K
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$3.0M+8.2%	$2.8M+9.2%	$2.6M-49.2%	$5.0M+4.6%	$4.8M-0.4%	$4.8M+2.9%	$4.7M+13.2%	$4.1M
Current Liabilities	$3.0M+8.2%	$2.8M+9.2%	$2.6M-49.2%	$5.0M+5.1%	$4.8M+1.3%	$4.7M+5.2%	$4.5M+13.6%	$4.0M
Long-Term Debt	$70K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$2.3M-17.5%	-$2.0M-17.5%	-$1.7M+58.4%	-$4.0M-9.0%	-$3.7M-7.2%	-$3.4M-9.4%	-$3.1M-24.0%	-$2.5M
Retained Earnings	-$8.0M-3.5%	-$7.7M-3.5%	-$7.5M-2.1%	-$7.3M-3.2%	-$7.1M-6.5%	-$6.7M-4.5%	-$6.4M-10.0%	-$5.8M

YBGJ Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$843K+37.0%	-$1.3M-81.0%	-$739K-23.0%	-$601K+41.1%	-$1.0M-1109.7%	$101K
Capital Expenditures	N/A	N/A	N/A	$0-100.0%	$565K+1227.0%	$43K
Free Cash Flow	N/A	N/A	N/A	-$601K+62.1%	-$1.6M-2808.0%	$59K
Investing Cash Flow	$0-100.0%	$118K	$0+100.0%	-$40K+93.0%	-$565K-479.4%	-$97K
Financing Cash Flow	$850K-39.6%	$1.4M+88.7%	$746K+11.4%	$669K+426.2%	$127K-90.8%	$1.4M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$207K-60.9%	-$129K+64.1%	-$359K-1069.1%	$37K+109.5%	-$392K+58.0%	-$933K-364.0%	$353K+182.6%	-$428K
Capital Expenditures	$0	N/A	N/A	N/A	$6K	N/A	N/A	N/A
Free Cash Flow	-$207K	N/A	N/A	N/A	-$398K	N/A	N/A	N/A
Investing Cash Flow	$0+100.0%	-$80K	$0-100.0%	$86K+1491.7%	-$6K	$0-100.0%	$36K-67.4%	$112K
Financing Cash Flow	$215K-42.9%	$376K	$0-100.0%	$196K-29.4%	$278K-75.0%	$1.1M+363.8%	-$421K-202.5%	$410K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

YBGJ Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	66.1%-10.2pp	76.3%+7.0pp	69.3%+18.8pp	50.5%-15.5pp	66.0%-25.6pp	91.6%
Operating Margin	-9614.6%+41391.7pp	-51006.3%-50808.7pp	-197.6%+958.1pp	-1155.7%-1031.7pp	-124.0%-71.4pp	-52.6%
Net Margin	-8736.7%+42434.7pp	-51171.4%-50973.8pp	-197.6%+957.9pp	-1155.5%-1031.5pp	-124.0%-71.4pp	-52.6%
Return on Equity	N/A	N/A	N/A	N/A	N/A	-61.0%
Return on Assets	-127.4%-11.7pp	-115.7%-44.0pp	-71.7%-20.4pp	-51.3%-17.7pp	-33.6%-4.5pp	-29.1%
Current Ratio	0.24+0.1	0.14-0.1	0.21-0.1	0.30-0.1	0.38-1.1	1.49
Debt-to-Equity	-1.43-0.0	-1.41+0.5	-1.90+3.2	-5.15+30.8	-35.96-37.1	1.09
FCF Margin	N/A	N/A	N/A	-576.3%-448.9pp	-127.4%-131.7pp	4.3%

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-38.4%	N/A	-32.5%-10.6pp	-21.9%+15.4pp	-37.4%	N/A	-37.5%-7.0pp	-30.5%
Current Ratio	0.20-0.0	0.24-0.0	0.25+0.1	0.13-0.0	0.140.0	0.14-0.0	0.16-0.0	0.19
Debt-to-Equity	-1.31+0.1	-1.43+0.1	-1.54-0.3	-1.26+0.1	-1.31+0.1	-1.41+0.1	-1.50+0.1	-1.64
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$2.0M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.24), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Frequently Asked Questions

What is Yubo International Biotech Limited's annual revenue?

Yubo International Biotech Limited (YBGJ) reported $12K in total revenue for fiscal year 2025. This represents a 256.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Yubo International Biotech Limited's revenue growing?

Yubo International Biotech Limited (YBGJ) revenue grew by 256% year-over-year, from $3K to $12K in fiscal year 2025.

Is Yubo International Biotech Limited profitable?

No, Yubo International Biotech Limited (YBGJ) reported a net income of -$1.1M in fiscal year 2025, with a net profit margin of -8736.7%.

What is Yubo International Biotech Limited's EBITDA?

Yubo International Biotech Limited (YBGJ) had EBITDA of -$1.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Yubo International Biotech Limited's gross margin?

Yubo International Biotech Limited (YBGJ) had a gross margin of 66.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Yubo International Biotech Limited's operating margin?

Yubo International Biotech Limited (YBGJ) had an operating margin of -9614.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Yubo International Biotech Limited's net profit margin?

Yubo International Biotech Limited (YBGJ) had a net profit margin of -8736.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Yubo International Biotech Limited's operating cash flow?

Yubo International Biotech Limited (YBGJ) generated -$843K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Yubo International Biotech Limited's total assets?

Yubo International Biotech Limited (YBGJ) had $847K in total assets as of fiscal year 2025, including both current and long-term assets.

What is Yubo International Biotech Limited's current ratio?

Yubo International Biotech Limited (YBGJ) had a current ratio of 0.24 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Yubo International Biotech Limited's debt-to-equity ratio?

Yubo International Biotech Limited (YBGJ) had a debt-to-equity ratio of -1.43 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Yubo International Biotech Limited's return on assets (ROA)?

Yubo International Biotech Limited (YBGJ) had a return on assets of -127.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Yubo International Biotech Limited's cash runway?

Based on fiscal year 2025 data, Yubo International Biotech Limited (YBGJ) had $8K in cash against an annual operating cash burn of $843K. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is Yubo International Biotech Limited's debt-to-equity ratio negative or unusual?

Yubo International Biotech Limited (YBGJ) has negative shareholder equity of -$2.0M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Yubo International Biotech Limited's Piotroski F-Score?

Yubo International Biotech Limited (YBGJ) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Yubo International Biotech Limited's earnings high quality?

Yubo International Biotech Limited (YBGJ) has an earnings quality ratio of 0.78x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Yubo International Biotech Limited?

Yubo International Biotech Limited (YBGJ) scores 13 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.